Academic Seminar: Research of antidote GMDTC for heavy metal cadmium poisoning
In order to deepen our students' knowledge of drug research and development, on the afternoon of December 1, 2022, Professor Henry Tong invited Professor Xiaojiang Tang, the head of Guangdong Medical Laboratory Animal Center, the director of the Chinese Society of Toxicology, the doctoral supervisor of the Southern Medical University, Guangzhou Jianersheng Pharmaceutical Co., Ltd., and the chairman of Zhuhai BesTest Bio-Tech Co., Ltd. to come to our AIDD Centre for lectures and exchanges. All the teachers and students of the AIDD Centre attended the lecture.
Professor Xiaojiang Tang shared the research and development process of the special antidote GMDTC for heavy metal poisoning and its potential application in clinical practice. GMDTC is an authorized invention patent compound obtained by Professor Xiaojiang Tang's team after 15 years of research, which can specifically remove cadmium ions and other heavy metals in the body. Professor Xiaojiang Tang's team creatively proposed that GMDTC uses the new mechanism of kidney tubular glucose reabsorption pathway (SGLT2-GLUT2 coupling) to drive cadmium, providing a new theory for the prevention and treatment of heavy metal poisoning. GMDTC is an "innovative product with a new mechanism and no listed drugs", an "orphan drug" with a major breakthrough, and a product of the "priority review and approval" of the Chinese Food and Drug Administration.
Professor Xiaojiang Tang's humorous teaching method and profound pharmaceutical knowledge have been highly praised by all teachers and students. Through this exchange and study, the students have benefited a lot and expanded the depth and breadth of knowledge in the field of pharmacy. It has deepened the students' understanding of the relevant fields of pharmacy, improved their cognitive level of drug research and development, and provided new research directions for the students' next study and research.
Professor Xiaojiang Tang, a doctor of Sun Yat-sen University and a postdoctoral fellow of the University of California, Berkeley, has served as the director of the Guangdong Medical Laboratory Animal Center and the director of the Chinese Society of Toxicology, and now serves as the doctoral supervisor of the Southern Medical University, the chairman of Guangzhou Jianersheng Pharmaceutical Co., Ltd., and the chairman of the Zhuhai BesTest Bio-Tech Co., Ltd. Professor Xiaojiang Tang is committed to the research and development of new drugs and the operation and management of bio-pharmaceutical public technology platform. He has undertaken more than 20 Sino-US international cooperation projects, the National Natural Science Foundation and other various projects, published more than 150 papers in domestic and foreign journals, revised and formulated 3 national standards, obtained 3 invention patents, and trained more than 20 doctoral and postgraduate students. He is the main author of the key evidence of formaldehyde-induced leukemia determined by IARC of the International Institute of Cancer. He has in-depth research on the prevention and control of heavy metal poisoning, and won the second prize of the excellent academic paper of the journal of the Chinese Association for Science and Technology on the prevention and control of organotin poisoning. He is the inventor of GMDTC, a new chemical drug with special effect to drive cadmium. The project won the Excellent Enterprise Award of the 7th China Innovation and Entrepreneurship Competition.
